Methylphenidate

Pregnancy

Human pregnancy evidence is observational and cannot fully separate medication effects from ADHD, other conditions, and health factors. Huybrechts et al. (2018) studied 1,813,894 US Medicaid pregnancies and 2,560,069 Nordic pregnancies ending in live births. The US methylphenidate estimates were RR 1.11 (95% CI 0.91-1.35) for any major malformation and RR 1.28 (95% CI 0.94-1.74) for cardiac malformations; the pooled cardiac estimate was RR 1.28 (95% CI 1.00-1.64). The EMA's 2019 review interpreted the data as no overall increase in birth defects but could not rule out a small cardiac risk; its product information estimated 3 additional cardiac defects per 1,000 first-trimester exposures. Diav-Citrin et al. (2016) followed 382 exposed pregnancies, 89.5% exposed in the first trimester. Major anomalies were similar to controls, while miscarriage was associated with methylphenidate exposure (aHR 1.98, 95% CI 1.23-3.20); past miscarriage was also a predictor. A 2024 meta-analysis of 10 studies and 16,621,481 pregnancies found no statistically significant increase in overall anomalies or miscarriage for methylphenidate and atomoxetine combined, but did not isolate methylphenidate. A Norwegian register-based case-control study among 13,298 pregnancies with ADHD found a methylphenidate prescription-fill association with miscarriage (aOR 1.55, 95% CI 1.35-1.79); the authors cautioned that fills may not reflect actual use. Cohen et al. (2017) included 1,515 methylphenidate-exposed pregnancies, but its later-pregnancy estimates were for stimulant medicines collectively; stimulant exposure was associated with preeclampsia (RR 1.29), and stimulant continuation after 20 weeks was associated with preterm birth (RR 1.30). Camacho et al. (2023) analyzed Ontario and New South Wales cohorts with nearly 700,000 pregnancies; most psychostimulant associations attenuated after adjustment, and preeclampsia findings were inconclusive. A 2026 Nordic cohort of 11,075 pregnancies reported a duration-related preterm-birth signal across ADHD medicines; the authors noted a late-pregnancy signal for methylphenidate but the abstract did not give a separate methylphenidate estimate. A 2026 US claims study of 10,265 matched patients reported increased pregnancy complications with stimulant continuation into the second or third trimester; it included multiple stimulant medicines and did not provide methylphenidate-specific estimates in the abstract. The 2023 MGH pregnancy registry reported no major malformations among 45 first-trimester methylphenidate exposures, but the sample was small. Suarez et al. (2024) found no meaningful overall neurodevelopmental-disorder increase after adjustment in US claims cohorts; a methylphenidate-ADHD association did not persist in sensitivity analyses with stricter control for maternal ADHD. Madsen et al. (2025) reported no increased risk of neurodevelopmental disorders, ADHD, or autism after adjustment, with consistent sibling comparisons. An Australian 2026 cohort reported gestational hypertension and diabetes associations for ADHD medicines overall, but the authors said the contribution of medicine versus ADHD was unclear.

Breastfeeding

The evidence during breastfeeding is small. LactMed reports very low milk levels and no detectable infant serum levels in limited measurements; it says treatment needed by the mother is not a reason to discontinue breastfeeding. MotherToBaby says prescribed use is not expected to cause infant problems and reports infants without side effects, but notes that methylphenidate may lower prolactin and that milk production has not been studied directly. The NHS says methylphenidate passes into milk in tiny amounts and recommends monitoring the infant. Kim et al. (2025) described one exclusively breastfeeding mother who began methylphenidate at three weeks postpartum; mother and infant were monitored for six months, with no reported effect on milk supply and normal infant growth and development. Bello et al. (2022) reported one mother who resumed methylphenidate at 13 weeks postpartum and continued pumping for seven months; the infant's growth remained appropriate. These case reports do not establish outcomes for other infants or long-term development. The CONCERTA label says no adverse effects on breastfed infants or milk production have been reported, but long-term neurodevelopmental effects are unknown and it lists infant monitoring for agitation, insomnia, reduced appetite, or reduced weight gain.

What was tested

Pregnancy evidence includes large administrative and Nordic registry cohorts, a prospective teratology-service cohort, meta-analyses, a small pregnancy registry, and population-based studies of maternal and birth outcomes. Outcomes include major and cardiac malformations, miscarriage, preeclampsia, preterm birth, growth, and child neurodevelopment. Many studies use prescription fills or records, so they cannot confirm that medicine was taken or fully remove confounding by ADHD and related health factors. Breastfeeding evidence includes small milk-level measurements, infant blood tests, clinical reports, and individual case reports; it does not establish long-term infant effects.